Author: OurCrowd

[MigVax in The Washington Post] Pills brings new hope in the global fight against covid-19

Nov 5, 2021 |

In the battle against covid-19, injected vaccines have been a game-changer in many countries. But while existing vaccines have stemmed a tide of cases in many high-income countries, massive disparities in supply have left many other countries without. Even when doses have arrived in these nations, there have been issues with distributing them before they reach their expiration date. On Thursday, a different front opened up in the battle against covid-19 — one that was notable for revolving around pills, rather than jabs. Read...

Read More
Newsletter: We made Oprah’s holiday list + Micro-robots in the brain

Newsletter: We made Oprah’s holiday list + Micro-robots in the brain

Nov 5, 2021 |

Top investment opportunities Startup of the Week: Bionaut micro-robot inside the brain OurCrowd Global Summit in Jerusalem, May 25, 2022 Oprah puts Tovala on holiday gift list Armani celebrates virtual Christmas with ByondXR NetOp: Preventing the next big tech crash Jay Steinfeld: Inside the mind of an entrepreneur ICON prints 100-home community with 3D technology OncoHost predicts cancer treatment response in patients FDA approves Insightec’s Parkinson’s ultrasound treatment IBM taps NeuReality to develop AI inference platforms Honeybook valuation soars to $2.4B with $250M Series E Salted raises $16M to expand US operations Autobrains raises $101M for AI-powered driving platform Introductions 3,600 high-tech jobs Startup of the Week:Bionaut: Micro-robot delivers drugs inside the brain A tiny robot could revolutionize treatment for brain disease and disorders in the central nervous system. The capsules developed by Bionaut Labs are custom-engineered therapeutic micro-robots that deliver drugs to specific locations in the body. Smaller than a millimeter, remote controlled by a compact magnetic controller, they can move through the brain and central nervous system, slice through tissue and release a therapeutic payload direct to...

Read More

[MigVax in CEPI] CEPI announces first funding awards in quest to develop ‘variant-proof’ COVID-19 vaccines

Nov 4, 2021 |

CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the first funding awards under its $200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses [1]. CEPI will support researchers at two institutions, MigVax Ltd, Israel, and the University of Saskatchewan’s (USask) Vaccine and Infectious Disease Organization (VIDO), Canada, as they seek to establish preclinical proof of concept for novel vaccines suitable for use in low-and middle-income countries that are broadly protective against COVID-19 variants. Read...

Read More